Gabapentin and Hepatitis cholestatic - a phase IV clinical study of FDA data

Summary:

Hepatitis cholestatic is reported as a side effect among people who take Gabapentin (gabapentin), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Paracetamol, and have Dyslipidaemia.

The phase IV clinical study analyzes which people have Hepatitis cholestatic when taking Gabapentin. It is created by eHealthMe based on reports of 313,421 people who have side effects when taking Gabapentin from the FDA, and is updated regularly.

What is Gabapentin?

Gabapentin has active ingredients of gabapentin. It is often used in neuralgia. eHealthMe is studying from 322,983 Gabapentin users. Check the latest studies of Gabapentin.

What is Hepatitis cholestatic?

Hepatitis cholestatic (flow of bile from the liver is slowed or blocked) is found to be associated with 544 drugs and 824 conditions by eHealthMe. Check the latest studies of Hepatitis cholestatic.

On Jul, 26, 2026

313,421 people reported to have side effects when taking Gabapentin.
Among them, 46 people (0.01%) have Hepatitis cholestatic.

Could Gabapentin cause Hepatitis cholestatic?

Among these 46 people:

How long have people been on Gabapentin when they have Hepatitis cholestatic? *

What is the gender of people who have Hepatitis cholestatic when taking Gabapentin? *

female: 42.86 %
male: 57.14 %

What is the age of people who have Hepatitis cholestatic when taking Gabapentin? *

What are other drugs people take besides Gabapentin? *

What are other side effects people have besides Hepatitis cholestatic? *

Hepatotoxicity (chemical-driven liver damage): 8 people, 17.39%
Jaundice - Yellow Skin (a yellowish pigmentation of the skin): 6 people, 13.04%
Myocarditis (inflammation of heart muscle myocardium): 5 people, 10.87%
Liver Injury: 4 people, 8.70%
Blood Bilirubin Increased: 4 people, 8.70%
Overdose: 4 people, 8.70%
Liver Function Tests Nos Abnormal: 3 people, 6.52%
Transaminases Increased: 3 people, 6.52%
Weakness: 2 people, 4.35%
Hepatic Enzyme Increased: 2 people, 4.35%

What are the existing conditions these people have? *

Depression: 8 people, 17.39%
Dyslipidaemia (abnormal amount of lipids): 8 people, 17.39%
Back Pain: 4 people, 8.70%
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 2 people, 4.35%
Herpes Zoster: 1 person, 2.17%
Constipation: 1 person, 2.17%
Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 1 person, 2.17%
Encephalopathy (functioning of the brain is affected by some agent or condition): 1 person, 2.17%
Von Hippel-Lindau Disease (genetic disease that causes tumours and cysts to grow in the body): 1 person, 2.17%
Trigeminal Neuralgia (a painful condition of the nerve responsible for most facial sensation): 1 person, 2.17%

* Approximation only. Some reports may have incomplete information.

Do you take Gabapentin and have Hepatitis cholestatic?

- Check whether Hepatitis cholestatic is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Gabapentin:

Gabapentin (322,983 reports)

Browse all side effects of Gabapentin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatitis cholestatic:

Hepatitis cholestatic (544 drugs)

Browse all the conditions that are associated with Hepatitis cholestatic:

Hepatitis cholestatic (824 conditions)

Related publications that referenced our studies

de Landaluce, L. O., Carbonell, P., Asensio, C., Escoda, N., López, P., & Laporte, J. R. , "Gabapentin and Pregabalin and Risk of Atrial Fibrillation in the Elderly: A Population-Based Cohort Study in an Electronic Prescription Database", Drug safety, 2018 Jan .
Scarff JR, "The Potential for Somnambulism Associated with Gabapentin", The Internet Journal of Psychiatry, 2014 Jan .
de Landaluce, L. O., Carbonell, P., Asensio, C., Escoda, N., López, P., & Laporte, J. R. , "Gabapentin and Pregabalin and Risk of Atrial Fibrillation in the Elderly: A Population-Based Cohort Study in an Electronic Prescription Database", Drug safety, 2018 Jan .
Scarff JR, "The Potential for Somnambulism Associated with Gabapentin", The Internet Journal of Psychiatry, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on gabapentin (the active ingredients of Gabapentin) and Gabapentin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.